Aernoud T L Fiolet, Willem Keusters, Johan Blokzijl, S Mark Nidorf, John E Eikelboom, Charley A Budgeon, Jan G P Tijssen, Tjeerd Römer, Iris Westendorp, Jan Hein Cornel, Peter L Thompson, Geert W J Frederix, Arend Mosterd, G Ardine de Wit
AIMS: Recent trials have shown that low-dose colchicine (0.5 mg once daily) reduces major cardiovascular events in patients with acute and chronic coronary syndromes. We aimed to estimate the cost-effectiveness of low-dose colchicine therapy in patients with chronic coronary disease when added to standard background therapy. METHODS AND RESULTS: This Markov cohort cost-effectiveness model used estimates of therapy effectiveness, transition probabilities, costs and quality of life obtained from the Low-dose Colchicine 2 (LoDoCo2) trial, as well as meta-analyses and public sources...
March 14, 2024: European Heart Journal. Quality of Care & Clinical Outcomes